News Edwards Lifesciences Corporation

Equities

EW

US28176E1082

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 05:00:02 24/01/2026 HKT			5-day change	1st Jan Change
83.66 ^USD	-0.92%		-0.82%	-1.87%

01-22	Leerink Partners Adjusts Edwards Lifesciences Price Target to $88 From $87, Maintains Market Perform Rating	MT
01-22	Venus Medtech Clarifies U.S. Patent Lawsuit Involving Subsidiary	MT

01-22	Leerink Partners Adjusts Edwards Lifesciences Price Target to $88 From $87, Maintains Market Perform Rating	MT
01-22	Venus Medtech Clarifies U.S. Patent Lawsuit Involving Subsidiary	MT
01-20	Piper Sandler Adjusts Price Target on Edwards Lifesciences to $98 From $95, Maintains Overweight Rating	MT
01-20	Stifel Adjusts Price Target on Edwards Lifesciences to $110 From $105, Maintains Buy Rating	MT
01-13	Edwards Lifesciences Corporation Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 11:15 AM
01-12	UBS Adjusts Price Target on Edwards Lifesciences to $95 From $92, Maintains Neutral Rating	MT
01-12	Independence, Under Review
01-12	Edwards Comments on JenaValve Acquisition	AQ
01-12	North American Morning Briefing : Stock Futures Fall, Gold Hits Record on Fed Concerns -2-	DJ
01-12	Barclays Adjusts Price Target on Edwards Lifesciences to $104 From $103, Maintains Overweight Rating	MT
01-12	Baird Adjusts Price Target on Edwards Lifesciences to $90 From $87, Maintains Neutral Rating	MT
01-12	RxSight Names Mark Wilterding Finance Chief	MT
01-12	Edwards Lifesciences Drops Bid to Acquire JenaValve Technology	MT
01-11	RxSight, Inc. Appoints Mark Wilterding as Chief Financial Officer, Effective January 11, 2026	CI
01-10	Edwards Lifesciences Drops Merger With JenaValve	DJ
01-10	Edwards says co will not acquire Jenavalve	RE
01-10	Edwards Comments on JenaValve Acquisition	BU
01-10	US FTC wins ruling blocking Edwards Lifesciences' acquisition of JenaValve	RE
01-09	Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $108 From $104, Maintains Buy Rating	MT
01-09	TD Cowen Upgrades Edwards Lifesciences to Buy From Hold, Adjusts Price Target to $97 From $90	MT
01-06	Evercore ISI Adjusts PT on Edwards Lifesciences to $94 From $92, Maintains Outperform Rating	MT
12-27	Federal Circuit Affirms Implicit Redefinition Of Claim Terms	AQ
12-25	HALPER SADEH LLC ENCOURAGES EDWARDS LIFESCIENCES CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS	PR
12-23	Edwards Lifesciences Says FDA Approves Valve Replacement System	MT
12-23	FDA approves Edwards Lifesciences' Sapien M3 mitral valve replacement system as first transseptal transcatheter therapy	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Edwards Lifesciences Corporation: The story continues

April 23, 2024 at 11:25 pm